Deerfield Management’s Aimmune Therapeutics AIMT Stock Holding History

Deerfield Management’s Portfolio AIMT Stock Details AIMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-339,480	Closed	-$7.11M	–	103
2019 Q3	$7.11M	Buy	+339,480	New	+$6.93M	0.29%	67
2018 Q4	–	Sell	-553,000	Closed	-$15.1M	–	114
2018 Q3	$15.1M	Sell	553,000 -120,000	-18%	-$3.39M	0.54%	57
2018 Q2	$18.1M	Sell	673,000 -37,210	-5%	-$1.14M	0.64%	58
2018 Q1	$22.6M	Buy	+710,210	New	+$25M	0.78%	51

Other funds holding AIMT

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Deerfield Management's AIMT Position: Q4 2019 in Review

Deerfield Management sold out of Aimmune Therapeutics (AIMT) in Q4 2019, closing a stake of 339,480 shares — an estimated $7.11M sold.

Deerfield Management first reported a position in AIMT in Q1 2018 and held it in 4 quarters. The position peaked at $22.6M in Q1 2018. 155 funds tracked by Wall St. Rank hold AIMT as of Q4 2019.

Deerfield Management reported no remaining Aimmune Therapeutics position as of Q4 2019 after selling out during the quarter.
Deerfield Management sold 339,480 Aimmune Therapeutics shares in Q4 2019, an estimated $7.11M.
Deerfield Management first reported a position in Aimmune Therapeutics in Q1 2018 and held it in 4 quarters.
Deerfield Management's Aimmune Therapeutics position peaked at $22.6M in Q1 2018.
155 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2019.

Based on Deerfield Management's 13F filing for Q4 2019, filed 14 Feb 2020.